Guangzhou Lupeng Pharmaceutical Company Ltd.

This study tests a new drug called rocbrutinib in adults with a type of aggressive lymphoma (non-GCB DLBCL) that has come back or not responded to treatment. About 150 participants will receive either rocbrutinib alone or one of two standard chemotherapy combinations. The main go…

This study tests an experimental oral drug called LP-168 in adults with B-cell lymphoma (a type of blood cancer) that has returned or stopped responding to standard treatments. The main goals are to find the safest dose and check for early signs that the drug can shrink tumors or…

This study tests a new drug called rocbrutinib for people with mantle cell lymphoma (MCL) that has come back or stopped responding to treatment. About 394 adults will either receive rocbrutinib or one of the standard BTK inhibitor drugs. The goal is to see if rocbrutinib can keep…

This study looks at how two common drugs—itraconazole (a fungus treatment) and rifampin (an antibiotic)—change the way the body processes rocbrutinib, an experimental medicine. Twenty-eight healthy adults will take rocbrutinib alone and then with each of the other drugs to measur…